Новостная лента

• 

  Haleon's reported strategic M&A dismissed as 'highly unlikely' and unwanted headache

  Proactive Investors

  01 февр 2023 г. в 08:50

  Haleon PLC's (LSE:HLN, NYSE:HLN) reported interest in large 'strategic scale' acquisitions, such as with Sanofi's consumer arm, have been panned by Barclays analysts as unlikely due to its need to reduce debt.  The maker of Senodybe toothpaste, Panadol pain relief and other respiratory and vitamins, minerals and supplement (VMS) brands was said by Bloomberg yesterday to be looking at transactions for the medium to long term, with Sanofi Consumer Health a potential US$30bn merger candidate.

• 

  Haleon: A Great Consumer Staples Add

  Seeking Alpha

  31 янв 2023 г. в 13:10

  Haleon's consumer brands are strong, and its free cash flow margin is high at 16%. Net debt to EBITDA is expected to decrease to 3x in 2024.

• 

  Haleon looks good on J&J read across, reckons Credit Suisse

  Proactive Investors

  25 янв 2023 г. в 10:06

  Haleon, the Glaxo personal care products spin-off, is an increasingly attractive option in the over-the-counter products space, according to Credit Suisse. Results this week from J&J Consumer Health's arm are directly comparable to Haleon, adds the broker, with a 55% overlap.

• 

  Successful Data Analysis Could Be Game Changer For Haleon

  Seeking Alpha

  20 янв 2023 г. в 06:16

  Haleon Plc is positioned as the world's largest company dedicated to the manufacture and marketing of personal care products. Haleon's power and positioning in the international market can be a bit better understood if we take into account its relationship with Pfizer and GSK plc.

• 

  GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

  Zacks Investment Research

  03 янв 2023 г. в 09:01

  GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.